GO29695 A Phase Ib study of the safety and pharmacokinetics of atezolizumab (ANTI-PD-L1 antibody) alone or in combination with an immunomodality drug and/or daratumumab in patients with multiple myeloma (relapsed/refractory and post-autologous stem cell transplantation)

November 08, 2018
https://clinicaltrials.gov/ct2/show/NCT02431208
Cancer - Myeloma
Principal Investigator: Nalini Janakiraman, MD
myeloma, atezolizumab
Accepting Participants